View clinical trials related to Nasal Carriers MRSA.
Filter by:This is a pilot study conducted to evaluate the safety, local tolerability and efficacy of LTX-109(Lytixarâ„¢), a lytic peptide designed to kill bacterias quickly and efficient. LTX-109 (Lytixarâ„¢)will be applied in the anterior nares in subjects who are carriers of nasal colonies of MRSA/MSSA. The extent of systemic absorption of LTX -109 when applied to the anterior nares will be evaluated and the effect of Lytixarâ„¢ as to clear colonies of MRSA/MSSA during the the observation period and Week 2 to Week 9 after treatment.